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Background: Although ventricular late potential (VLP) was extensively studied in risk stratification of myocardial
infarction (MI) patients, comparable researches evaluating presence of VLP in MI-free coronary artery disease (CAD)
and cardiac syndrome X (CSX) subjects are scarce. This study aimed to compare presence of VLP between CSX and
CAD patients.
Methods: Signal average ECG (SAECG) was performed to 49 patients with a history of typical cardiac pain before
undergoing diagnostic coronary angiography (DCA) in Al-Shaab cardiac center, Khartoum, Sudan. QRS duration,
duration of the terminal part of the QRS complex with amplitude less than 40 microvolts (LAS40) and the root
mean square voltage of the terminal 40 milliseconds (RMS40) of the filtered QRS complex were identified for each
patient. Presence of two or more of QRS duration > 120 ms, RMS40 > 38 ms and LAS40 < 20 μV was considered
indicative of VLP. Associations between VLP and patients grouped according to DCA results were assessed using
appropriate statistical tests.
Results: VLP was present in 11.11% (3.63%–24.66%) and 15.38% (2.66%–42.23%) of patients with CAD and CSX
respectively. Presence of VLP was comparable in patients with CAD and CSX (OR = 0.69, 95% CI = 0.11–6.05, P = 0.
692), even after controlling for the possible variations in gender, age, body mass index (BMI), hypertension and
diabetes mellitus in the studied groups.
Conclusion: Presence of VLP is comparable among CSX and CAD patients.
Keywords: Cardiac syndrome X, Coronary artery disease, Ventricular late potential
Background
Slow transmission of myocardial depolarization usually
forms low amplitude, high frequency waveforms at the
end of QRS complex in electrocardiogram (ECG)
known as ventricular late potential (VLPs) [1, 2]. Signal
average ECG (SAECG) technique is commonly used to
improve the resolution of ECG so that the small ampli-
tude VLPs can be measured [3]. VLP is considered as
an electrophysiological indicator for reentry ventricular
arrhythmia and sudden cardiac death [4]. Although
VLP was extensively studied for risk stratification of
myocardial infarction (MI) patients [5–7], comparable
researches evaluating VLP in MI-free coronary artery
disease (CAD) and cardiac syndrome X (CSX) subjects are
scarce [8]. CSX is mostly attributed to coronary micro-
vascular ischemia [9] and diagnosed if a subject suffered
typical angina attack(s), demonstrated positive cardiac
stress test(s) but had normal coronary angiography [10].
Positive VLP was recognized in patients with hyperten-
sion [11, 12], diabetes mellitus [13, 14], obesity [15, 16]
and other indicators of metabolic syndrome [17, 18].
Bearing in mind that metabolic syndrome is common in
patients with CSX [19] as well as CAD [20, 21], it is
likely that VLP coexists with these conditions putting
the affected patients at risk of ventricular arrhythmia. In
theory, this implication is further supported by the fact
that myocardial ischemia, whether macrovascular (CAD)
or microvascular (CSX), can induce slowing of cardiac
depolarization and thus formation of VLP [1–4]. This
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study aimed to compare presence of VLP between CSX
and CAD patients. In addition, influence of gender, age,
body mass index (BMI), hypertension and diabetes melli-
tus on the presence of VLP was assessed among the
studied groups.
Methods
The present study gained ethical approval from ethics re-
view committee (ERC) - Faculty of Medicine - Khartoum
University - Sudan. All subjects enrolled in the study
signed a written informed consent before being evaluated.
Forty nine patients with a history of typical cardiac pain
were evaluated in Al-Shaab cardiac center, Khartoum,
Sudan, before undergoing diagnostic coronary angiography
(DCA). Past medical history and clinical examination were
performed guided by prearranged questionnaire. BMI was
calculated by subdividing weight (Kg) by squared height
(m2). Mean arterial blood pressure (MABP) was estimated
from systolic (SBP) and diastolic blood pressure (DBP) by
the formula: MABP ¼ DBP þ 13 SBP‐DBPð Þ.
DCA demonstrated narrowing of ≥ half of the caliber
of ≥ one of the major coronary artery/arteries in 36 of
the studied patients and were considered as CAD [22].
The remaining studied patients (N = 13) were diagnosed
as CSX according to Lee et al criteria [23].
After connecting three orthogonal bipolar electrodes
(XYZ lead system), 5-min SAECG was recorded for each
patient using Bluetooth ECG transmitter and receiver
(DM systems (Beijing) Co. limited - China). The Blue-
tooth ECG signals received were averaged, amplified and
filtered between 25 Hz and 250 Hz. The following
SAECG indices were measured: QRS duration, duration
of the terminal part of the QRS complex with an ampli-
tude less than 40 microvolts (LAS40) and the root mean
square voltage of the terminal 40 milliseconds (RMS40)
of the filtered QRS complex. The durations of QRS and
LAS40 were measured in milliseconds (ms) while RMS40
was measured in microvolts (μV). QRS duration > 120 ms,
RMS40 > 38 ms and LAS40 < 20 μV were considered ab-
normal [24]. Presence of two or more abnormal SAECG
measurements was considered indicative of VLP [24, 25].
Statistical package for the social sciences (SPSS) for
windows, version 16.0 (SPSS Inc., Chicago, IL, USA) and
OpenEpi calculator (version 2.3) were used for statistical
evaluation of the studied parameters. Means, medians,
standard deviations (SD), 25 quartile (Q1) and 75 quar-
tile (Q3) were used to describe studied variables based
on their distribution curves [26]. Proportions of the
studied groups were expressed in percentages (%) and
95% confidence intervals (CI). Means (SD) and median
(Q1-Q3) of normally and abnormally distributed vari-
ables were compared in the studied groups using Stu-
dent’s T and Mann-Whitney U tests, respectively. Mid-P
exact test was used to evaluate the association between
VLP and CAD/CSX. The associations between presence
of VLP and CAD/CSX, gender, age, BMI, hypertension
and diabetes mellitus were assessed by binary logistic re-
gression analysis. The odds ratio (OR) was used to de-
scribed the ratio of the odds of an event occurring in
patients with CAD to the odds of the same event occur-
ring in subject with CSX. P < 0.05 was considered
significant.
Results
CSX patients constituted 26.53% (N = 13, 95% CI = 16.21–
40.26%) of the subjects who performed DCA (N = 49).
There remaining patients 73.47% (N = 36, 59.74–83.79%)
were proved to suffer from CAD. Males constituted
53.85% (29.14–76.79%) and 63.89% (47.58–77.52%) of
CSX and CAD patients respectively. Compared with CSX
subjects, CAD patients have higher distribution of dia-
betes mellitus (Chi2 = 4.738, P = 0.030), significantly in-
creased age (46.69 (6.71) vs. 59.47 (10.31) years, P < 0.001),
but decreased BMI (29.37 (4.39) vs. 25.83 (4.33) kg/m2,
P = 0.016), Table 1. Distribution of gender (Chi2 = 0.406,
P = 0.524) and hypertension (Chi2 = 0,057, P = 0.812)
were comparable among CSX and CAD patients. N (%)
of CAD patient with angiographically defined coronary
artery/arteries stenosis are given in Table 2.
VLP was present in 11.11% (3.63–24.66%) and 15.38%
(2.66–42.23%) of patients with CAD and CSX respect-
ively. Occurrence of VLP was comparable in patients
with CAD and CSX (OR = 0.69, 95% CI = 0.11–6.05, P =
0.692), Table 3. According to the results of binary logis-
tic regression, the comparable distribution of VLP
among CAD and CSX patient persisted after controlling
for the possible variations of gender, age, BMI, hyperten-
sion and diabetes mellitus in the studied groups, Table 4.
Discussion
It is evident from the results that VLP was present in
more than 12% of patients undergoing DCA, being com-
parably distributed among patients with CAD and CSX.
Table 1 Distribution of age, BMI, MABP and SAECG indices










Age (Years) 58.00 (54.25–67.50) 50.00 (40.00–50.50) < 0.001
BMI (kg/m2) 25.83 (4.33) 29.37 (4.39) 0.016
MABP (mmHg) 95.43 (14.73) 98.62 (18.15) 0.540
QRS (ms) 84.00 (79.00–104.0) 81.00 (79.00–92.00) 0.403
LAS40 (ms) 31.00 (25.25–34.00) 31.00 (19.00–34.50) 0.777
RMS40 (μV) 113.31 (66.80) 87.64 (51.64) 0.225
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Previous reports demonstrated VLP in 4–6% of healthy
subjects [27, 28]. Comparable studies evaluating inci-
dence of VLP in patient with CAD are mostly confined
to those with MI [5–7]. To our best of knowledge, the
present study is the first to evaluate existence of VLP in
patients with CSX. In an old study, positive VLP was
documented in 24% of CAD patients with no previous
MI and successful thrombolytic therapy received within
4 h of symptom onset [29]. According to Yang et al, the
prevalence of VLP in patients with acute MI increased
from 32% in the day admission to 52% in the following
7–10 days [6]. Alternatively, Zaman demonstrated posi-
tive VLP in 29% of patients with acute MI at the day of
admission, 42% after 1 week and 13% after 6 weeks [7].
Compared with the above narrative, the present study
confirmed VLP in 11% and 15% of patients with CAD
and CSX respectively. Based on our results and previous
reports, incidence of VLP among studied patients with
CAD and CSX are equally higher than normal subjects
[27, 28], but still lower compared with patients with
well-established MI [6, 7].
Noteworthy, there is concern about the low positive
predictive value of VLP. According to Santangeli et al.,
the strength of VLP is dependent on its high negative
predictive value [3]. However, when positive, VLPs can
faithfully stratify the arrhythmic risk of patients in sev-
eral clinical settings. According to the same study, VLP
was highly predictive of cardiac events in patients with
ischemic heart diseases, but neither arrhythmogenic
right ventricular cardiomyopathy nor syncope of un-
known cause. As justified earlier, the aim of our study
was to assess risk of VLP in ischemic myocardium
whether secondary to macrovascular (CAD) or micro-
vascular (CSX) coronary dysfunction. The comparable
distribution of VLP among studied CSX and CAD
patients suggests comparable risk of both groups to
cardiac events.
Studies on VLP among patients with CAD were
mostly evaluating this parameter as a potential pre-
dictor of ventricular arrhythmia following myocardial
infarction [5, 30]. It was suggested that VLP originate
from viable areas around acutely infarcted myocardium
[31] or interspersed between fibrous tissues of an old
MI [32]. In such conditions, VLP is favored by dis-
turbed architecture of myocardial fibers caused by ne-
crosis and/or fibrosis that ultimately resulted in slow
and fragmented depolarization [33]. VLP therefore rep-
resent delayed propagation of depolarization waves
through a diseased myocardium putting affected patient
at higher risk of reentry ventricular arrhythmias [3].
Alternatively, myocardial ischemia induced by micro-
vascular dysfunction is likely to compromise ventricular
depolarization and forms the basis for VLP among CSX
patients [9]. Old age [17, 18], hypertension [11, 12],
diabetes mellitus [13, 14], obesity [15, 16] and other
indicators of metabolic syndrome are common in CSX
patients [34], and were proved to increase the risk of
VLP. Taking into consideration all these risk factors for
VLP, it is evident that the tendency of CAD and CSX
patients towards abnormal SAECG is comparable. This
implication is further supported by our results, which
showed not statistical difference in distribution of posi-
tive VLP between these groups.
Structural and functional changes that increase the
risk of VLP on senescent heart include myocyte hyper-
trophy, interstitial fibrosis, variation of depolarization
propagation velocities and heterogeneity of myocardial
refractive periods [35, 36]. Left ventricular hypertrophy
and relative myocardial ischemia associated with hyper-
tension may induce slowing of cardiac impulse and
Table 2 N (%) of CAD patients with angiographically defined
coronary artery/arteries stenosis/stenoses
Coronary artery Main branches N (%)
Left coronary artery Left main coronary trunk 3 (8.33%)
Anterior descending artery 32 (88.89%)
Circumflex artery 12 (33.33%)
Right coronary artery Right main coronary trunk 15 (41.67%)
Posterior descending artery 2 (5.56%)
Marginal artery 8 (22.22%)
Table 3 Association between VLP and CAD/CSX
VLP Present VLP Absent Total
CAD N 4 32 36
% 11.11% 88.89% 100%
95% CI 3.63–24.66% 75.34–96.37% 90.36–100%
CSX N 2 11 13
% 15.38% 84.62% 100%
95% CI 2.664–42.23% 57.77–97.34% 77.19–100%
Total N 6 43 49
% 12.24% 87.76% 100%
95% CI 5.12–23.74% 76.26–94.88% 92.73–100%
Mid-P exact test was used because at least one expected value (row total*column
total/grand total) is less than 5, OR = 0.69, 95% CI = 0.11–6.05, P = 0.692
Table 4 Binary logistic regression analysis of factors associated VLP
OR (95% CI) P
CAD vs. CSX 0.68 (0.07–6.71) 0.741
Male gender 3.72 (0.36–38.62) 0.272
Age > 50 Years 1.35 (0.13–14.07) 0.803
BMI > 25 Kg/m2 3.88 (0.39–39.14) 0.250
Hypertension 0.61 (0.09–4.17) 0.613
Diabetes Mellitus 0.68 (0.09–5.11) 0.710
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predispose to formation of VLP [11, 12]. In experimental
animals, Streptozocin induced diabetes mellitus interferes
with both cardiac depolarization and repolarization [13].
Autonomic neuropathy associated with insulin resistance
gives another explanation for higher risk of diabetic pa-
tient to develop VLP [14]. Myocardial injury induced
by lipotoxicity [37], parasympathetic withdrawal [38]
and insulin resistance [39] are proposed causes of ab-
normal SAECG in obese subjects [15, 16]. Noteworthy,
the comparable distribution of VLP among CAD and
CSX patient we studied persisted after we controlled
for the possible variations of gender, age, BMI, hyper-
tension and diabetes mellitus in the studied groups
using binary logistic regression. Although it is difficult
to explain the lack of association between risk factors
for VLP and abnormal SAECG findings in the present
study, comparable negative findings were demonstrated
by another study investigating VLP in patients with is-
chemic heart disease (IHD) [8]. According to Banasiak
et al, comparison of IHD patients with and without VLP
showed no discriminating characteristics of the investi-
gated groups, including results of echocardiography, exer-
cise and 24-h Holter ambulatory monitoring [8]. Further
investigations are needed to explain why associations
between VLP and some of its physiological/pathological
determinants are occasionally hidden in patients with
coronary macro- or microvascular dysfunctions.
Noteworthy, calculation of appropriate sample size
using the formula for unmatched case control study
was difficult before collecting the data of this research.
For estimation of ideal sample size, the percentages of
CAD and CSX patient with positive VLP should be
predetermined. However, the percentage CSX patient
with positive VLP was not investigated before. Alter-
natively, different percentages CAD patients with posi-
tive VLP were described in the literature but none of
them were derived from MI-free CAD patients. The
exploratory findings of present study should motivate
researchers in the field for more investigations. The
sample size of such studies is now easy to determine
based on the present findings. Further studies based
on properly determined sample size are expected to
minimize the disparate number CAD and CSX pa-
tients in the present study. Moreover, longitudinal
follow-up of patients with CSX and VLP are essential
in future studies to prove the prognostic implications
of the present findings. Another limitation of the
present study is the lack of angina-free healthy control
group. Coronary angiography and cardiac stress tests
are important for exclusion of CAD and CSX in an
ideal control group. Ethically, both tests are difficult
to perform in patients with no cardiac complaints,
particularly elder individuals. This precluded presence
of a control group in the present study.
Conclusions
The present study is the first to evaluate presence of
VLP in patients with CSX. Results showed comparable
distribution of VLP among CSX and CAD subjects sug-
gesting a comparable risk of both groups to cardiac
events.
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